Shaires (AIM: SHR) builds $86.7m private AI portfolio as London investors weigh access against dilution

Shaires Holdings Ltd (AIM: SHR) is attempting an unusually ambitious transformation into a London-listed gateway to some of the world’s highest-valued private technology companies, assembling an initial portfolio worth up to US$86.7 million with exposure to Anthropic, ByteDance, Stripe, Figure AI, SandboxAQ, Moonshot AI and Colossal Biosciences. The company is financing that strategy through a combination of cash investments, special-purpose vehicles, binding options, in-kind contributions and newly issued Shaires shares, while targeting approximately US$100 million of capital across institutional and retail fundraising and initial non-cash contributions. Shaires priced its first US$28.5 million institutional tranche at US$20 per share and subsequently launched a United Kingdom retail offer at the same price, an 18% discount to the US$24.50 closing price immediately before the Capital Access Window began. The attraction for public-market investors is obvious, but the more important analytical question is whether access to highly sought-after private companies compensates for substantial new-share issuance, indirect ownership structures and the challenge of establishing independently observable portfolio valuations.

Shaires voluntarily paused trading in its shares under a Capital Access Window while the retail financing was conducted, with the offer scheduled to close on August 18 and the result expected around August 19. The mechanism comes as London attempts to make its growth markets more useful for companies seeking capital, and Shaires is positioning itself as a test case for whether AIM can connect ordinary public-market investors with late-stage private technology assets that would normally remain inside venture capital, employee holdings and specialist secondary funds. The potential portfolio is compelling by name recognition, but investors will need to look beyond those names because several exposures are indirect and some commitments remain subject to options, allocations or customary completion conditions rather than representing completed direct shareholdings in the underlying companies.

How is Shaires building an US$86.7 million portfolio around Anthropic, ByteDance and other private AI companies?

The proposed initial portfolio contains seven private technology businesses across frontier artificial intelligence, payments, robotics, quantum-related technology and biotechnology. Shaires disclosed binding arrangements providing up to US$16.2 million of exposure to Anthropic, US$15 million to ByteDance, approximately US$14.8 million to SandboxAQ, up to US$14.5 million to Figure AI, approximately US$12 million to Colossal Biosciences, around US$9.2 million to Stripe and US$5 million to Moonshot AI. In aggregate, the company describes those commitments as an initial portfolio worth up to US$86.7 million, although completion conditions vary by transaction and the figure should not be interpreted as cash already invested in seven directly owned stakes.

The structure is central to understanding what shareholders are actually receiving. The Anthropic, Stripe and Figure AI positions are expected to come through special-purpose vehicles managed by Rizvi Traverse, while the ByteDance investment is an indirect holding through a dedicated share class within a regulated Luxembourg fund. Shaires’ Moonshot AI commitment similarly involves participating shares in an Abu Dhabi Global Market special-purpose vehicle whose underlying asset is an interest in Moonshot AI. Investors therefore gain economic exposure to the private companies, but they generally do not receive the governance rights that would accompany direct ownership of the underlying shares.

That distinction does not make the investments inherently less valuable, because private-company secondary markets frequently rely on funds and SPVs to aggregate ownership and manage transfer restrictions. It does, however, mean investors need to understand fees, liquidity, voting rights, transfer constraints and the precise economic rights attached to each structure rather than treating every dollar of reported portfolio exposure as equivalent.

Why is the related-party structure around Anthropic, Stripe and Figure AI important for Shaires shareholders?

Up to US$40 million of Shaires’ initial portfolio could be invested through SPVs managed by Rizvi Traverse, a business controlled by Shaires Executive Chairman Suhail Rizvi and therefore treated as a related party. The allocation comprises up to US$16.2 million for Anthropic, up to US$14.5 million for Figure AI and approximately US$9.3 million for Stripe. Suhail Rizvi did not participate in the Shaires board’s consideration of the transaction, while Rizvi Traverse agreed to waive customary carried interest and other fees associated with the SPVs. Shaires said its independent directors, after consultation with its nominated adviser, considered the terms fair and reasonable for shareholders.

The related-party element deserves precision rather than alarmist treatment. Shaires is effectively using relationships associated with its chairman to obtain access to private-company interests that are difficult for small public-market investment vehicles to source independently. If those relationships produce access on competitive economic terms, they can be strategically valuable. The governance test is whether valuation, fees and transaction economics remain transparent enough for shareholders to determine that Shaires itself, rather than an affiliated intermediary, captures the value created by that access.

The scale makes the issue material. US$40 million represents approximately 46% of the US$86.7 million maximum initial portfolio announced by Shaires. In other words, almost half of the contemplated day-one portfolio could depend on the Rizvi Traverse SPV structure, making the quality of those arrangements central to the investment proposition rather than a peripheral disclosure.

At what valuations is Shaires getting exposure to Anthropic, Figure AI and Stripe?

The private-company valuations being used are already substantial. Shaires said the Figure AI exposure would be acquired at the company’s September 2025 Series C valuation of approximately US$39 billion, equivalent to around US$194.93 per share. Stripe exposure is based on the payments company’s February 2026 tender valuation of approximately US$159 billion, or around US$63 per share. The Anthropic SPV investment is based on a disclosed Series H valuation of approximately US$965 billion, equivalent to around US$589.01 per share.

Those numbers illustrate why Shaires should not be analysed like an early-stage venture capital vehicle buying companies before institutional price discovery. It is acquiring exposure after these businesses have already attracted enormous amounts of private capital and reached valuations normally associated with major public companies. The upside therefore depends increasingly on operating growth justifying already demanding entry valuations rather than on simple multiple expansion from a small startup base.

That does not mean further value creation is impossible. Companies such as Anthropic, Stripe and Figure AI are pursuing exceptionally large markets, and late-stage private businesses can continue growing substantially before eventually entering public markets or being acquired. The valuation challenge is that public Shaires shareholders must assess those possibilities without the regular audited financial disclosure, daily price discovery and analyst coverage normally available for comparably valued listed companies.

What is Shaires actually paying for its US$15 million ByteDance exposure?

Shaires’ ByteDance transaction provides a useful example of why headline commitment values and effective transaction costs need to be separated. The company committed US$15 million for an indirect position in ByteDance Series B preferred shares through a regulated Luxembourg fund, giving Shaires an estimated economic interest of only around 0.003% in the private technology group. The underlying shares were priced at US$355.50 each, corresponding to an entry valuation of approximately US$585 billion.

Including the disclosed 6% upfront fee, the total cash outlay is approximately US$15.9 million and the effective all-in valuation rises to about US$620 billion. That does not automatically make the transaction unattractive, because the fee may reflect the scarcity and administrative complexity of obtaining company-approved secondary access to ByteDance. It does mean that the investment needs to appreciate beyond the transaction cost before generating an economic return for Shaires.

The same principle applies across the portfolio. Access to desirable private companies has a price, and Shaires’ investment performance will ultimately depend on the value realised after SPV expenses, entry fees, dilution at the Shaires level and any other transaction costs rather than on the headline valuation movements of the underlying companies alone.

How much dilution is Shaires accepting to acquire SandboxAQ and Colossal Biosciences exposure?

Two of the most interesting transactions use Shaires shares rather than cash. Approximately US$14.8 million of SandboxAQ exposure is being contributed in exchange for 741,821 new Shaires shares, while the roughly US$12 million Colossal Biosciences transaction involves 600,000 Shaires shares. Both contributions are being valued at US$20 per newly issued Shaires share, creating approximately US$26.8 million of combined in-kind consideration.

Following admission of those 1,341,821 consideration shares, Shaires expects to have approximately 3.84 million ordinary shares outstanding before incorporating any additional shares that may arise from subsequent fundraising. On that disclosed share count, the SandboxAQ and Colossal consideration shares alone would represent roughly 35% of the enlarged equity base. This is meaningful dilution, although shareholders are receiving private technology assets in return rather than simply seeing shares issued to fund operating losses.

The central valuation question is whether the assets being contributed are worth at least the value of the Shaires equity being issued. Colossal exposure was acquired at approximately US$24.89 per underlying Colossal share, corresponding to a fully diluted valuation of about US$10.3 billion, while Shaires also obtained arrangements potentially allowing it to acquire additional Colossal shares from existing holders. The initial contributed position represents roughly 0.1% of Colossal’s issued shares.

For shareholders, this makes NAV discipline crucial. Issuing stock can be highly accretive when a company exchanges overvalued shares for undervalued assets, but destructive when the opposite occurs. Shaires will therefore need credible and consistently applied valuation policies to demonstrate whether its in-kind exchange model increases value per share rather than simply increasing portfolio size.

Why does the US$20 fundraising price matter after Shaires shares closed at US$24.50?

Shaires’ first institutional tranche issued 1.424 million shares at US$20 each, generating approximately US$28.48 million of gross proceeds and increasing cash resources to around US$36.5 million when combined with approximately US$8 million already held by the company. Those subscription shares represented about 57% of the post-admission share capital at the time, highlighting how dramatically the company’s ownership base has already changed as it finances the new strategy.

The subsequent retail offer was also priced at US$20, compared with a US$24.50 mid-market close on August 12, representing a discount of approximately 18%. Shaires entered a Capital Access Window from August 13 while the retail transaction was conducted, so investors have not had continuous normal-market price discovery during the fundraising period.

The discount can be interpreted in two ways. It gives new investors an entry point below the pre-window market price and helps the company attract enough capital to assemble a meaningful portfolio. Existing shareholders, however, experience dilution when large numbers of shares are issued below the previous quoted market price. Whether that dilution proves economically worthwhile depends on what Shaires buys with the capital and whether the resulting portfolio produces NAV growth comfortably above the dilution created.

Could Shaires’ Capital Access Window become a test case for London’s attempt to revive AIM?

The timing gives the transaction significance beyond Shaires itself. AIM has been undergoing changes intended to make the market more useful for growth companies seeking capital, while London’s broader equity market is confronting a sustained decline in listings and continuing take-private activity. The London Stock Exchange describes AIM as a growth market designed to provide smaller and medium-sized companies with flexible access to capital, and recent reforms have focused heavily on reducing friction around fundraising.

Shaires is trying to use that infrastructure in a way that reverses the usual private-market narrative. Instead of a promising technology company leaving public markets because private capital is deeper, Shaires is attempting to bring private-market assets into a publicly tradeable structure. If the model succeeds, London investors could obtain exposure to companies that might otherwise remain inaccessible until an eventual initial public offering.

The challenge is that accessibility alone does not guarantee good investment economics. A public wrapper can make the Shaires shares tradeable, but it cannot make the underlying Anthropic, ByteDance or Figure AI stakes themselves continuously liquid. The company will need to manage the mismatch between a quoted security and a portfolio dominated by private assets whose valuations change episodically through funding rounds, tender offers and secondary transactions.

What would make Shaires trade at a premium or discount to the value of its private AI portfolio?

Once normal trading resumes and the expanded portfolio settles, Shaires could theoretically trade either above or below its reported NAV. A premium could emerge if investors value the scarcity of publicly accessible exposure to companies such as Anthropic, ByteDance and Stripe, particularly if comparable routes involve high minimum commitments or specialist private funds. A discount could emerge if investors question valuation transparency, liquidity, governance, future dilution or the ability to realise the private investments at their reported carrying values.

This is a familiar issue for listed investment companies, but Shaires intensifies it because several of the underlying businesses are high-profile private technology companies with enormous valuations and limited public financial disclosure. A sharp increase in the valuation of one portfolio company could raise reported NAV substantially, while an adverse funding round or weaker secondary-market price could have the opposite effect without Shaires itself changing its operations.

Management’s decision to operate Shaires without management or performance fees is consequently important because it removes one common layer of investment-company cost. It does not eliminate transaction fees attached to individual private-market structures, as illustrated by the disclosed ByteDance and Moonshot AI arrangements, so shareholders will still need to assess portfolio-level friction rather than focusing solely on the absence of a conventional fund-management charge.

What must Shaires prove after assembling a portfolio containing some of private technology’s biggest names?

The company’s first test is completion. The US$86.7 million figure contains a mixture of investments, options and in-kind contributions, meaning investors need confirmation of which transactions have closed, the final amounts deployed and the precise number of shares issued to fund them. Shaires has also said it is discussing further opportunities as it seeks to build a portfolio exceeding US$500 million in the near term, but those discussions are not completed assets and should not be incorporated into current portfolio value until definitive agreements are reached.

The second test is NAV reporting. Shaires needs to show that valuations are based on observable and defensible private-market reference points and that changes in carrying value are explained clearly enough for public shareholders to distinguish genuine portfolio appreciation from changes in methodology. With the transaction price of US$20 and approximately 3.84 million shares expected after the SandboxAQ and Colossal consideration issuance, that disclosed share count produces an equity reference value of roughly US$76.8 million before any further retail or institutional shares are included. This is not an NAV calculation, but it demonstrates how quickly the relationship between portfolio commitments, new capital and share count is evolving.

The third test is dilution discipline. Shaires has designed an in-kind model that could become powerful if holders of private technology shares willingly exchange those assets for Shaires equity at sensible valuations. If successful, the company can grow without funding every acquisition in cash. If shares are issued too aggressively or the contributed private assets subsequently prove overvalued, however, portfolio growth would not necessarily translate into value growth for each existing Shaires share.

Shaires has succeeded in creating something genuinely unusual for the London market: a small AIM company attempting to aggregate economic exposure to Anthropic, ByteDance, Stripe, Figure AI, SandboxAQ, Moonshot AI and Colossal Biosciences into a publicly accessible vehicle. The names create the attention, but they are not yet the proof of the investment case. That proof will come from the relationship between NAV growth and share-count growth, the economics of the indirect investment structures and Shaires’ ability to demonstrate that its access to scarce private assets produces more value per share than the dilution required to obtain them.

Key takeaways from Shaires Holdings’ US$86.7 million private AI portfolio strategy

• Shaires Holdings has announced an initial private technology portfolio worth up to US$86.7 million, subject to the completion terms attached to individual investments.
• The proposed portfolio includes exposure to Anthropic, ByteDance, Stripe, Figure AI, SandboxAQ, Moonshot AI and Colossal Biosciences.
• Up to US$40 million of exposure to Anthropic, Stripe and Figure AI is expected through SPVs managed by Rizvi Traverse, a related party controlled by Shaires Executive Chairman Suhail Rizvi.
• Rizvi Traverse has waived customary carried interest and other fees on those SPV investments, while Suhail Rizvi did not participate in the board’s consideration of the related-party transaction.
• Shaires invested US$15 million in indirect ByteDance exposure at a US$585 billion underlying valuation, with a 6% upfront fee taking the total cash outlay to approximately US$15.9 million.
• SandboxAQ and Colossal Biosciences positions are being acquired partly through approximately US$26.8 million of in-kind consideration using newly issued Shaires shares.
• Shaires’ first institutional fundraising tranche generated approximately US$28.5 million at US$20 per share and lifted cash resources to roughly US$36.5 million.
• The United Kingdom retail offer was also priced at US$20, approximately 18% below the US$24.50 share price immediately before the Capital Access Window.
• The investment case depends on more than access to high-profile companies because shareholders also face private-asset valuation risk, indirect ownership structures and substantial potential dilution.
• The decisive evidence will be whether Shaires can increase NAV per share as it expands toward its stated ambition of building a portfolio exceeding US$500 million.